Canada Antitrust Watchdog Rejects Probe Over Drug-Patent Evergreening Tactics

Law360, New York (February 28, 2004, 12:00 AM EST) -- Canada’s competition watchdog sent a probe over price gouging by drug companies back to the federal government, suggesting it review the country’s current patent laws.

The Competition Bureau said it doesn't have the jurisdiction to continue probing a controversial drug patent law and argued it was an issue for politicians in Ottawa.

"The government may wish to review the current rules to ensure that an appropriate balance is maintained between protecting intellectual property rights and facilitating a competitive supply of pharmaceutical products for Canadian consumers," the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.